



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



LPA₂ Antagonist 1

Item No. 22051

CAS Registry No.: 1017606-66-4
Formal Name: N-[(1S)-2-[4-[(3,4-dichlorophenyl)sulfonyl]-1-piperazinyl]-1-methylethyl]-7-methyl-thieno[3,2-d]pyrimidin-4-amine
MF: C₂₀H₂₃Cl₂N₅O₂S₂
FW: 500.5
Purity: ≥98%
UV/Vis.: λ_{max}: 242, 302 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

LPA₂ antagonist 1 is supplied as a crystalline solid. A stock solution may be made by dissolving the LPA₂ antagonist 1 in the solvent of choice. LPA₂ antagonist 1 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of LPA₂ antagonist 1 in these solvents is approximately 30 mg/ml.

LPA₂ antagonist 1 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, LPA₂ antagonist 1 should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. LPA₂ antagonist 1 has a solubility of approximately 0.33 mg/ml in a 1:2 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

LPA₂ antagonist 1 is an antagonist of lysophosphatidic acid receptor 2 (LPA₂; IC₅₀ = 17 nM).¹ It is selective for LPA₂ over LPA₁ and LPA₃ (IC₅₀s = >50 μM). LPA₂ antagonist 1 inhibits HGF-induced phosphorylation of ERK and proliferation of HCT116 colon cancer cells in a concentration-dependent manner.

Reference

1. Beck, H.P., Kohn, T., Rubenstein, S., *et al.* Discovery of potent LPA₂ (EDG4) antagonists as potential anticancer agents. *Bioorg. Med. Chem. Lett.* **18(3)**, 1037-1041 (2008).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/08/2018

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM